PUBLISHER: The Business Research Company | PRODUCT CODE: 1763105
PUBLISHER: The Business Research Company | PRODUCT CODE: 1763105
Vectibix (panitumumab) is a monoclonal antibody used to treat metastatic colorectal cancer (mCRC). It targets the epidermal growth factor receptor (EGFR), a protein found on the surface of certain cancer cells. By binding to EGFR, panitumumab prevents its activation by natural growth factors, thereby inhibiting the signaling pathways that promote cell division and tumor growth.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The key distribution channels for vectibix include hospital pharmacies and online pharmacies. Hospital pharmacies provide medications to both inpatients and outpatients within healthcare facilities as part of integrated medical care. The drug is primarily used for treating colorectal cancer and other cancer types, with end-users including hospitals, clinics, and ambulatory surgical centers.
The vectibix (panitumumab) market research report is one of a series of new reports from The Business Research Company that provides vectibix (panitumumab) market statistics, including vectibix (panitumumab) industry global market size, regional shares, competitors with a vectibix (panitumumab) market share, detailed vectibix (panitumumab) market segments, market trends and opportunities, and any further data you may need to thrive in the vectibix (panitumumab) industry. This vectibix (panitumumab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The vectibix (panitumumab) market size is expected to see strong growth in the next few years. It will grow to $1,853.9 million in 2029 at a compound annual growth rate (CAGR) of 8%. The growth in the forecast period can be attributed to increasing prevalence of metastatic colorectal cancer (mcrc) globally, growing focus on personalized medicine, increasing healthcare spending in emerging markets, growing adoption of biologics in oncology, increasing focus on patient quality of life. Major trends in the forecast period include advancements in anti-EGFR therapies, partnerships and collaborations between pharmaceutical companies, integration of advanced diagnostic tools, development of companion diagnostics, adoption of next-generation sequencing.
The increasing prevalence of colorectal cancer is expected to drive the growth of the vectibix (panitumumab) market in the coming years. Colorectal cancer, which begins in the colon or rectum, is influenced by factors such as aging, genetic predispositions, and environmental influences. The rising incidence of colorectal cancer is linked to an aging population, better survival rates, and improved detection methods. Vectibix (panitumumab), a monoclonal antibody, targets and inhibits the epidermal growth factor receptor (EGFR) to slow tumor growth and progression in patients with wild-type KRAS tumors. This offers an effective treatment for patients who do not respond to conventional chemotherapy. According to the World Health Organization (WHO), the global burden of colorectal cancer is expected to increase significantly by 2040, with 3.2 million new cases annually, a 63% rise. This growing prevalence is poised to drive the demand for vectibix.
The rising demand for personalized medicine is a key factor propelling the growth of the vectibix (panitumumab) market. Personalized medicine tailors treatments based on individual patient characteristics, including genetic profiles. Advances in genomic technologies, improved understanding of molecular biology, and the availability of precision diagnostic tools have made personalized therapies more common. Vectibix is used as a personalized treatment for metastatic colorectal cancer by targeting the EGFR on cancer cells, particularly in patients whose tumors express wild-type EGFR. This targeted approach improves therapeutic efficacy and minimizes side effects. For example, in February 2023, the Personalized Medicine Coalition highlighted that the FDA approved several important indications for in vitro diagnostic testing, contributing to the rising demand for personalized medicine. This trend further supports the growth of the vectibix market.
A significant trend in the vectibix market is the development of molecular diagnostic products, such as companion diagnostic kits, which help identify the most suitable patients for targeted therapies. Companion diagnostic kits detect specific biomarkers or genetic mutations, ensuring that treatments like Vectibix are given to patients who are most likely to benefit. In October 2023, EntroGen Inc. received FDA approval for the CRCdx RAS Mutation Detection Kit as a companion diagnostic for Vectibix. This kit, which detects mutations in KRAS and NRAS genes, helps clinicians identify patients who would benefit from Vectibix, ensuring more effective treatment while minimizing unnecessary side effects and costs. This trend towards personalized diagnostics is enhancing the precision of Vectibix therapy and contributing to the market's growth.
The Key player operating in the vectibix (panitumumab) market is Amgen Inc.
North America was the largest region in the vectibix (panitumumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in vectibix (panitumumab) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the vectibix (panitumumab) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The vectibix (panitumumab) market consists of sales of chemotherapy combination products, nutritional supplements, supportive care medications and related products. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Vectibix (panitumumab) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on vectibix (panitumumab) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for vectibix (panitumumab) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The vectibix (panitumumab) market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.